Mon, May 13, 2019
Fri, May 10, 2019
Thu, May 9, 2019
Wed, May 8, 2019
Tue, May 7, 2019
Mon, May 6, 2019

Geoff Meacham Maintained (BIIB) at Hold with Decreased Target to $245 on, May 9th, 2019

Geoff Meacham of Barclays, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $250 to $245 on, May 9th, 2019.

Geoff has made no other calls on BIIB in the last 4 months.



There are 12 other peers that have a rating on BIIB. Out of the 12 peers that are also analyzing BIIB, 10 agree with Geoff's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Downgraded from Strong Buy to Hold on, Friday, March 22nd, 2019
  • Robyn Karnauskas of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $230 on, Friday, March 22nd, 2019
  • Salim Syed of "Mizuho" Downgraded from Strong Buy to Hold and Decreased Target to $235 on, Friday, March 22nd, 2019
  • Sumant Kulkarni of "Canaccord Genuity" Downgraded from Strong Buy to Hold and Decreased Target to $275 on, Friday, March 22nd, 2019
  • Matt Phipps of "William Blair" Downgraded from Buy to Hold on, Thursday, March 21st, 2019
  • Steve Chesney of "Atlantic Equities" Downgraded from Buy to Hold on, Thursday, March 21st, 2019
  • Alethia Young of "Cantor Fitzgerald" Downgraded from Buy to Hold on, Thursday, March 21st, 2019
  • Adnan Butt of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $325 on, Friday, February 22nd, 2019
  • Ian Somaiya of "BMO Capital" Initiated at Hold and Held Target at $322 on, Friday, February 22nd, 2019
  • Thomas Shrader of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $346 on, Thursday, February 21st, 2019


These are the ratings of the 2 analyists that currently disagree with Geoff


  • Christopher Marai of "Nomura" Maintained at Strong Buy with Decreased Target to $320 on, Friday, March 22nd, 2019
  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Sell on, Friday, March 22nd, 2019